GAITHERSBURG, Md., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ:NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious...
GAITHERSBURG, Md., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ:NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious...
Investing.com – U.S. stocks were lower after the close on Wednesday, as losses in the Oil & Gas, Basic Materials and Technology sectors led shares lower. At the close in NYSE, the...
Novavax, Inc. (NASDAQ:NVAX) announced that it has initiated a phase III study on its nanoparticle seasonal influenza vaccine candidate NanoFlu. The pivotal study will evaluate...
For Immediate ReleaseChicago, IL – September 30, 2019 - Stocks in this week’s article are Odonate Therapeutics, Inc. (NASDAQ:ODT) , Novavax, Inc. (NASDAQ:NVAX) ,...
Constant earnings growth captivates almost everyone, right from the top brass to research analysts. This is because earnings are a measure of the money a company is making....
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Buy||Sell||Strong Sell||Strong Sell||Buy|
|Technical Indicators||BUY||Strong Sell||Strong Sell||Strong Sell||Neutral|
|Summary||Buy||Strong Sell||Strong Sell||Strong Sell||Neutral|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Outside Up||15||Current|
|Belt Hold Bullish||30||Current|
|Bullish doji Star||5H||Current|
|Bullish Engulfing||15||1||Oct 22, 2019 03:30PM|
|Morning Doji Star||15||1||Oct 22, 2019 03:30PM|
|Morning Star||15||1||Oct 22, 2019 03:30PM|
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).Read More
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.